Effect of Patient Education on Compliance and Cardiovascular Risk Parameters (FAILAKA)
Effect of Patient Awareness and Education on Compliance and Cardiovascular Risk Factor Control
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Prospective cluster randomized interventional study with primary health care clinics as clusters.Clinics will be randomized to conventional care or to structured patient education in addition to care. Trained physicians will extract information from the patient medical record and will conduct a personal interview with the participants, after they finish with their routine visit, to fill a case report form (CRF)
CRF will include the following items:
- Patient Demographics,
- Socioeconomic: income, employment and education
- Past Medical History
- Smoking history
- Alcohol use
- Medications
- Adherence: Morisky scale
- Examination: BP, weight, height, waist
- Investigations: LDL-C, HbA1C 2.Compliance/adherence to the medication will be measured by using the Morisky scale, which is a validated scale for measuring adherence in hypertension and diabetic patients among other disease.
Patients attending clinics that are randomized to structured patient education will receive education targeting all the risk factors they have. They will be informed about specific evidence -based target values they should achieve for each of the risk factors. Their compliance to prescribed medications will be encouraged and specific advice about improving compliance will be given. To achieve this physicians in the education clinics are going to use two items:
- Framingham Risk Score calculator.
- Know your numbers patient booklet.
Follow up visits will be scheduled at 2 months, 6 months and 12 months after the initial visit. For patients in both education and conventional clinics, compliance to medications will be assessed and the degree of risk factor control will also be determined through specific measurements that include number of cigarettes smoked, systolic and diastolic blood pressure, body mass index and waist circumference, HBA1C and LDL values.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with one or more CVD risk factors will be consecutively enrolled, smokers and obese patients should have an additional risk factors
- The risk factors are based on Framingham Risk Score calculator and include smoking, high blood pressure, high blood cholesterol ,diabetes and being overweight or obese
- All participants must be adults (30 -70 years of age) who give an informed consent
- All participants should be of Kuwaity nationality, literate and fluent in either Arabic or English
- Patients are likely to be available for a one year follow up
Exclusion Criteria:
- Patients with mental disability or severe psychiatric disorder who are unable to provide informed consent or participate in educational activities.
- Patients with severe visual or hearing disability that will prevent participation in the educational activity
- Patients <30 years or >70 years of age
- Illiterate patients
- Non Kuwaity nationals
- Patients who are not permanently resident in Kuwait
- Patient who refuse to provide the informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Patient Education
|
Patient Education using the following two instruments:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
cardiovascualr risk factor control
Délai: 12 months
|
Cardiovascular risk factors control as assessed by the following parameters: HbA1C, Blood pressure, LDL-C, BMI and smoking cessation
|
12 months
|
|
medication compliance
Délai: 12 months
|
Medication compliance as assessed by Morisky scale
|
12 months
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Samia Almusallam, FRCGP, Kuwait Institute for Medical Specialization
- Chercheur principal: Maleka M Serour, MRCGP/ INT, Kuwait Institute for Medical Specialization
- Chercheur principal: Wafa A Rashed, FRCP, Ministry of Health -Mubarak Hospital- Cardiology unit
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- WS964765
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .